https://www.selleckchem.com/pr....oducts/SB-203580.htm
VPA treatment notably improved pSer133-cAMP response element-binding protein (CRE and brain-derived neurotrophic factor (BDNF) levels, which are associated with synaptic function and neurite outgrowth. VPA improves behavioral deficits in AD, modifies synaptic structure, and accelerates neurite outgrowth, by inhibiting the activity of GSK-3β, decreasing hyperphosphorylated tau, enhancing CREB and BDNF expression. VPA improves behavioral deficits in AD, modifies synaptic structure, and accelerates neurite outgrowth, by inhibiting the